FDA Inspection
GlaxoSmithKline, LLC.GlaxoSmithKline, LLC. – FDA Inspection, Mar 7, 2025
Record Details
This FDA Inspection record concerns GlaxoSmithKline, LLC., with an inspection on March 7, 2025, issued by the Philadelphia District Office, covering human drugs.
View Company Profile
ID · b8f525fd-c7f3-4be7-96cb-3b6521628f55
Inspection Facts
- Inspection number
- 1274978
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of GlaxoSmithKline, LLC.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 15, 2026 | Not classified | Philadelphia District Office | |
| September 25, 2024 | Not classified | Philadelphia District Office | |
| June 20, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 26, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 8, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for GlaxoSmithKline, LLC.
- FDA Inspection 1332910 - 2026-07-15
- FDA Inspection 1261906 - 2024-09-25
- FDA Inspection 1211050 - 2023-06-20
- FDA Inspection 1043309 - 2018-01-26
- FDA Inspection 927643 - 2015-05-08
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.